AstraZeneca and BYD in Focus: China’s 2025 Biotech & EV Revolution
China’s capital markets are reopening to foreign investors—but only for those nimble enough to navigate a new era of regulatory opacity and geopolitical risk. After years of de-risking from Western ... Read More